CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 151 enrolled
Drug / intervention
DSXS1411 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02413229
NCT02413229Phase 2Completed
CompareCT.gov

A Randomized Double Blind Vehicle Controlled Dose Ranging Multiple Site Phase 2 Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Moderate to Severe Scalp Psoriasis

Sun Pharmaceutical Industries, Inc.·interventional·Posted Apr 9, 2015·Updated Dec 6, 2018

In Brief

A Phase 2 clinical trial evaluating DSXS1411 and Placebo for Plaque Psoriasis. Completed, enrolled 151 participants.

Detailed Summary

The objectives of this study are to evaluate the therapeutic efficacy and safety of DSXS and a Placebo in patients with moderate to severe scalp psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 9, 2015
Enrollment StartApr 1, 2015
Primary CompletionSep 14, 2015
Study CompletionJan 29, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 11.2 years ago

Interventions

DSXS1411drug

DSXS (Taro Pharmaceuticals Inc.)

Placebodrug

Placebo (vehicle) (Taro Pharmaceuticals Inc.)